TABLE 3.

Recommended duration of antiviral prophylaxis against HBV reactivation

Guideline	Recommended duration
AASLD	6 mo after completion of immunosuppressive therapy
AGA	≥12 mo after completion of B-cell–depleting therapies ≥6 mo after completion of all other immunosuppressive therapies
ASCO	12 mo after completion of B-cell–depleting therapies 6 mo after completion of other chemotherapies
EASL	18 mo after completion of B-cell–depleting therapies 12 mo after completion of other immunosuppressive therapies
APASL	Consider termination 6 mo after completion depending on HBV serologies and degree of underlying liver fibrosis

Abbreviations: AGA, American Gastroenterological Association; APASL, Asian Pacific Association for the Study of the Liver; ASCO, American Society for Clinical Oncology (ASCO); EASL, European Association for the Study of the Liver.